NASDAQ · SAVAW
Cassava Sciences, Inc. Warrant
Healthcare · Biotechnology
$0.03
Up+$0.00 (+0.00%)
Updated Aug 14, 2026, 8:19 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.45M
- P/E ratio
- —
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 2.51M
- Avg. volume
- 331K
Price performance
SAVAW price history
1M range · 0 trading sessions · Daily adjusted prices
SAVAW does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest SAVAW news
The latest Smart Investors Daily articles mentioning SAVAW.
Stock researchCompany · Overview
SAVAW research
Overview
Company profile and research snapshot.
Company profile
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
